Request Free Sample ×
South Korea Inflammatory Bowel Disease Treatment Market Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

South Korea Inflammatory Bowel Disease Treatment Market

ID: MRFR/MED/54706-HCR
200 Pages
Satyendra Maurya
April 2026

South Korea Inflammatory Bowel Disease Treatment Market Research Report: Size, Share, Trend Analysis By Drug Type (Aminosalicylates, Corticosteroids, Immunomodulators, Biologics, Antibiotics), By Route of Administration (Oral, Injectable, Topical), By Disease Type (Ulcerative Colitis, Crohn's Disease) and By End Users (Hospitals, Ambulatory Surgical Centers, Homecare Settings) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

South Korea Inflammatory Bowel Disease Treatment Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

South Korea Inflammatory Bowel Disease Treatment Market Summary

As per Market Research Future analysis, the South Korea Inflammatory Bowel Disease Treatment Market Size was estimated at 600.0 USD Million in 2024. The South Korea inflammatory bowel-disease-treatment market is projected to grow from 633.12 USD Million in 2025 to 1083.75 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 5.5% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The South Korea inflammatory bowel-disease-treatment market is experiencing robust growth driven by increasing awareness and advancements in treatment options.

  • The market is witnessing a rising incidence of inflammatory bowel diseases, indicating a growing patient population.
  • Advancements in treatment modalities are enhancing therapeutic options, particularly in biologics and biosimilars.
  • Regulatory support for new therapies is fostering innovation and expediting the approval process for novel treatments.
  • Key market drivers include increasing awareness and diagnosis, alongside rising healthcare expenditure, which are propelling market growth.

Market Size & Forecast

2024 Market Size 600.0 (USD Million)
2035 Market Size 1083.75 (USD Million)
CAGR (2025 - 2035) 5.52%

Major Players

AbbVie (US), Johnson & Johnson (US), Bristol-Myers Squibb (US), Takeda Pharmaceutical Company (JP), Amgen (US), Gilead Sciences (US), Merck & Co. (US), Sanofi (FR), Ferring Pharmaceuticals (CH)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

South Korea Inflammatory Bowel Disease Treatment Market Trends

The inflammatory bowel-disease-treatment market is currently experiencing notable developments, driven by an increasing prevalence of conditions such as Crohn's disease and ulcerative colitis. In South Korea, the growing awareness of these diseases among healthcare professionals and patients is fostering a more proactive approach to treatment. This shift is likely to enhance the demand for innovative therapies, including biologics and biosimilars, which are becoming more accessible. Furthermore, the integration of advanced technologies in treatment protocols appears to be improving patient outcomes, thereby influencing market dynamics positively. In addition, the regulatory environment in South Korea is evolving, with authorities focusing on expediting the approval processes for new treatments. This regulatory support may encourage pharmaceutical companies to invest in research and development, potentially leading to the introduction of novel therapies in the market. As the healthcare system continues to adapt to the needs of patients with inflammatory bowel diseases, the market is poised for growth, reflecting a commitment to improving the quality of care and treatment options available to patients in the region.

Rising Incidence of Inflammatory Bowel Diseases

The increasing number of diagnosed cases of inflammatory bowel diseases in South Korea is prompting a surge in demand for effective treatment options. This trend indicates a growing recognition of these conditions, leading to enhanced healthcare initiatives and patient education.

Advancements in Treatment Modalities

Innovations in treatment modalities, particularly the development of biologics and biosimilars, are shaping the landscape of the inflammatory bowel-disease-treatment market. These advancements are likely to provide patients with more effective and targeted therapies.

Regulatory Support for New Therapies

The South Korean regulatory framework is becoming more supportive of new therapies, facilitating quicker approvals for innovative treatments. This trend may encourage pharmaceutical companies to focus on research and development, ultimately benefiting patients.

South Korea Inflammatory Bowel Disease Treatment Market Drivers

Rising Healthcare Expenditure

The increasing healthcare expenditure in South Korea is a significant driver for the inflammatory bowel-disease-treatment market. As the government and private sectors invest more in healthcare services, the availability of advanced treatment options is expanding. In 2025, healthcare spending is projected to reach approximately $200 billion, with a notable portion allocated to chronic disease management, including inflammatory bowel diseases. This trend indicates a growing recognition of the importance of effective treatment for chronic conditions, which is likely to enhance the market for IBD therapies. Additionally, higher healthcare spending may lead to improved infrastructure and access to specialized care, further supporting the growth of the inflammatory bowel-disease-treatment market. The correlation between increased healthcare investment and market expansion suggests a positive outlook for future developments.

Government Initiatives and Funding

Government initiatives aimed at improving healthcare access and funding for inflammatory bowel disease research are pivotal in shaping the treatment market in South Korea. The government has allocated substantial resources to support research and development of new therapies, which is expected to enhance treatment options available to patients. In 2025, public funding for IBD-related research is anticipated to exceed $50 million, reflecting a commitment to addressing the needs of this patient population. Furthermore, policies promoting the inclusion of innovative treatments in national health insurance coverage are likely to increase patient access to necessary therapies. This supportive regulatory environment fosters a conducive atmosphere for pharmaceutical companies to invest in the inflammatory bowel-disease-treatment market, ultimately benefiting patients through improved treatment availability and affordability.

Increasing Awareness and Diagnosis

The rising awareness of inflammatory bowel diseases (IBD) in South Korea is a crucial driver for the inflammatory bowel-disease-treatment market. Enhanced public education campaigns and healthcare provider training have led to earlier diagnosis and treatment. As a result, the number of diagnosed cases has increased, contributing to market growth. In 2025, it is estimated that approximately 0.5 million individuals in South Korea are living with IBD, which represents a significant increase from previous years. This growing patient population necessitates a wider range of treatment options, thereby stimulating demand for innovative therapies and medications. Furthermore, increased awareness among patients about the importance of seeking medical help for gastrointestinal symptoms is likely to drive market expansion, as more individuals are encouraged to pursue treatment options.

Technological Innovations in Treatment

Technological advancements in the treatment of inflammatory bowel diseases are significantly influencing the market landscape in South Korea. The introduction of biologics and biosimilars has transformed treatment protocols, offering more effective and targeted therapies for patients. In 2025, the market for biologics is projected to account for over 40% of the total inflammatory bowel-disease-treatment market, reflecting a shift towards precision medicine. Additionally, the development of digital health solutions, such as telemedicine and mobile health applications, is enhancing patient management and adherence to treatment regimens. These innovations not only improve patient outcomes but also create new opportunities for pharmaceutical companies to introduce novel therapies, thereby driving market growth. The integration of technology into treatment strategies appears to be a key factor in shaping the future of the inflammatory bowel-disease-treatment market.

Patient-Centric Approaches in Treatment

The shift towards patient-centric approaches in the treatment of inflammatory bowel diseases is emerging as a key driver in the market. Healthcare providers in South Korea are increasingly focusing on personalized treatment plans that consider individual patient needs and preferences. This trend is likely to enhance patient satisfaction and adherence to treatment regimens, which is crucial for managing chronic conditions like IBD. In 2025, it is estimated that patient engagement initiatives will lead to a 20% increase in treatment adherence rates among IBD patients. Furthermore, the emphasis on shared decision-making between patients and healthcare providers is expected to foster a more collaborative treatment environment. This patient-centric focus not only improves health outcomes but also drives demand for diverse treatment options, thereby positively impacting the inflammatory bowel-disease-treatment market.

Market Segment Insights

By Type: Biologics (Largest) vs. Aminosalicylates (Fastest-Growing)

In the South Korea inflammatory bowel-disease-treatment market, Biologics hold the largest market share among the various treatment options available, showcasing their effectiveness and preferred status among healthcare providers and patients alike. On the other hand, Aminosalicylates have emerged as the fastest-growing segment, driven by increasing patient awareness and the continuous development of new formulations that enhance treatment adherence and efficacy. The growth trends within this segment are significantly influenced by factors such as rising incidences of inflammatory bowel diseases and advancements in biotechnology. The ongoing research into novel therapeutic agents and the increasing approval of biologics are set to further strengthen their market position. Additionally, the affordability and accessibility of Aminosalicylates are factors contributing to their swift growth trajectory, making them a crucial component of treatment protocols moving forward.

Biologics (Dominant) vs. Aminosalicylates (Emerging)

Biologics represent the dominant force in the South Korea inflammatory bowel-disease-treatment market, recognized for their innovative mechanisms targeting specific inflammatory pathways. With extensive clinical studies backing their efficacy, they are often the first line of treatment for moderate to severe cases. In contrast, Aminosalicylates, known for their anti-inflammatory properties, are emerging as a preferred choice for mild to moderate cases, particularly among patients seeking long-term management solutions. The growing trend towards personalized medicine is creating opportunities for these segments to thrive in their respective niches. While Biologics demand a complex manufacturing and administration process, Aminosalicylates offer a more straightforward regimen with fewer side effects, establishing them as an appealing option for patients and physicians alike.

By Route of Administration: Oral (Largest) vs. Injectable (Fastest-Growing)

In the South Korea inflammatory bowel-disease-treatment market, the route of administration segment is primarily dominated by the oral category, which significantly contributes to the overall treatment strategies adopted by healthcare professionals. The oral route has established a substantial share due to its convenience, patient compliance, and established efficacy in managing gastrointestinal disorders. Conversely, the injectable route is gaining traction, accounting for an increasing market share as advancements in formulations and drug delivery methods enhance its appeal. Recent growth trends in this segment indicate a rising preference for injectable formulations, as they are associated with rapid onset of action and increased bioavailability. Additionally, the growing awareness of preventive treatments for inflammatory bowel disease is propelling the injectable category, making it the fastest-growing segment. Technological innovations and improved patient education further contribute to this positive outlook for the injectable route.

Oral (Dominant) vs. Injectable (Emerging)

The oral route is the dominant method of administration in the South Korea inflammatory bowel-disease-treatment market, characterized by its ease of use and high patient acceptance. Formulations are designed for optimal absorption and therapeutic effectiveness, making oral treatments a preferred choice for many patients. On the other hand, the injectable route represents an emerging trend, focused on delivering biologics and advanced therapies that require direct entry into the systemic circulation. This method is particularly suitable for patients who require rapid relief from severe symptoms, positioning it as a valuable option in modern treatment protocols.

By Disease Type: Ulcerative Colitis (Largest) vs. Crohn's Disease (Fastest-Growing)

In the South Korea inflammatory bowel-disease-treatment market, Ulcerative Colitis currently holds a significant portion of the market share, being recognized as the largest segment due to its prevalence among patients. This condition is commonly diagnosed in individuals, leading to an extensive demand for specialized treatments and care. Conversely, Crohn's Disease, though comparatively smaller in market share, is gaining traction as it experiences rapid growth, driven by increased awareness and improved diagnostic methods. The growth trends within the South Korea inflammatory bowel-disease-treatment market indicate a promising future for both segments. Ulcerative Colitis is expected to maintain its dominance, supported by a robust portfolio of treatment options and established care pathways. On the other hand, Crohn's Disease is projected to expand rapidly, fueled by advancements in therapies and a broader recognition of the condition's impact on quality of life. The focus on research and development in this area is also anticipated to drive innovation, further enhancing the treatment landscape.

Ulcerative Colitis (Dominant) vs. Crohn's Disease (Emerging)

Ulcerative Colitis is the dominant segment in the South Korea inflammatory bowel-disease-treatment market, characterized by its significant prevalence and the availability of various treatment modalities that cater to patient needs. It is marked by a chronic inflammatory condition affecting the colon, which necessitates ongoing medical intervention. In contrast, Crohn's Disease is emerging rapidly, with increasing recognition in clinical practice leading to an upsurge in treatment options. It presents with diverse symptoms due to its ability to impact any part of the gastrointestinal tract. The evolution of targeted therapies and biologics is transforming Crohn's treatment, making it more effective and tailored to individual patient profiles. As awareness grows, the emerging segment is expected to attract more investment and innovation.

By End User: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing)

In the South Korea inflammatory bowel-disease-treatment market, Hospitals represent the largest share of the end-user segment. They are well-equipped with specialized staff and facilities that cater to the complex needs of patients suffering from inflammatory bowel diseases (IBD). Ambulatory Surgical Centers, on the other hand, are gaining traction, providing cost-effective alternatives for certain procedures. These centers are becoming more popular among patients who prefer less invasive treatments and shorter recovery times. The growth trends within this segment reveal a notable shift towards outpatient care driven by advancements in medical technology and patient preferences for less invasive options. Hospitals remain critical for severe cases, but Ambulatory Surgical Centers are expanding their services rapidly. Homecare settings are also emerging, appealing to the growing demand for personalized, at-home treatment plans for IBD patients. The convenience of homecare often enhances patient satisfaction and adherence to treatment regimens.

Hospitals (Dominant) vs. Ambulatory Surgical Centers (Emerging)

Hospitals dominate the South Korea inflammatory bowel-disease-treatment market, providing a comprehensive range of services, including diagnosis, treatment, and post-operative care. Their extensive resources enable them to handle complex cases, making them the preferred choice for many patients. In contrast, Ambulatory Surgical Centers are emerging rapidly, focusing on specialized outpatient procedures that enhance patient convenience and reduce costs. These centers are equipped with advanced technologies that facilitate quicker recovery times, attracting a growing segment of patients. While Hospitals are perceived as traditional care providers, the rise of Ambulatory Surgical Centers reflects a notable shift towards more innovative, patient-centric care options that aim to improve overall treatment experiences.

Get more detailed insights about South Korea Inflammatory Bowel Disease Treatment Market
Request Free Sample

Key Players and Competitive Insights

The inflammatory bowel-disease-treatment market in South Korea is characterized by a dynamic competitive landscape, driven by increasing prevalence rates and a growing demand for innovative therapies. Major players such as AbbVie (US), Johnson & Johnson (US), and Takeda Pharmaceutical Company (JP) are strategically positioned to leverage their extensive research and development capabilities. AbbVie (US) focuses on enhancing its portfolio through continuous innovation, particularly with its flagship product, Humira, while also exploring biosimilars to maintain market share. Johnson & Johnson (US) emphasizes partnerships and collaborations to expand its therapeutic offerings, particularly in biologics, which are gaining traction in the treatment of inflammatory bowel diseases. Takeda Pharmaceutical Company (JP) is actively pursuing regional expansion and localized manufacturing to optimize its supply chain and meet the specific needs of the South Korean market.The market structure appears moderately fragmented, with several key players vying for dominance. Business tactics such as localizing manufacturing and optimizing supply chains are becoming increasingly important as companies seek to enhance operational efficiency and reduce costs. The collective influence of these major players shapes the competitive environment, fostering a landscape where innovation and strategic partnerships are paramount.

In October AbbVie (US) announced a significant investment in a new research facility in South Korea, aimed at accelerating the development of next-generation therapies for inflammatory bowel disease. This move underscores AbbVie's commitment to innovation and its intent to strengthen its foothold in the region. The establishment of this facility is likely to enhance local R&D capabilities, potentially leading to faster drug development timelines and improved patient outcomes.

In September Johnson & Johnson (US) entered into a strategic partnership with a local biotech firm to co-develop a novel biologic therapy targeting inflammatory bowel disease. This collaboration not only expands Johnson & Johnson's product pipeline but also allows for the integration of local expertise, which may enhance the therapeutic relevance of their offerings in the South Korean market. Such partnerships are indicative of a broader trend towards localized innovation in the pharmaceutical sector.

In August Takeda Pharmaceutical Company (JP) launched a new digital health initiative aimed at improving patient engagement and adherence to treatment regimens for inflammatory bowel disease. This initiative leverages technology to provide patients with personalized support and education, reflecting a growing trend towards digitalization in healthcare. By enhancing patient experience and outcomes, Takeda positions itself as a leader in patient-centric care.

As of November current competitive trends in the inflammatory bowel-disease-treatment market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, as companies strive to meet the complex needs of patients and healthcare providers.

Key Companies in the South Korea Inflammatory Bowel Disease Treatment Market include

Industry Developments

Recent developments in the South Korea Inflammatory Bowel Disease Treatment Market have shown significant movement in 2023, with various pharmaceutical companies enhancing their presence. Pfizer, Merck, and AbbVie continue to lead with innovative treatments, directly impacting market growth.

The launch of new therapies by Roche and Takeda Pharmaceutical in early 2023 has drawn increased attention and investment in the sector. Notably, in August 2023, Amgen announced its collaboration with Mylan to develop biosimilars for inflammatory bowel conditions.

Additionally, Ferring Pharmaceuticals has initiated clinical trials for novel therapies, marking a substantial step forward in Research and Development efforts tailored for the South Korean demographic. The market has seen a valuation increase as a result of companies focusing on personalized medicine, which caters specifically to the unique genetic profiles of South Korean patients.

Over the last two years, significant regulatory changes in May 2022 encouraged faster approvals for new treatments, which has facilitated a competitive landscape. This environment fosters innovation and collaboration, with players such as Johnson and Johnson and Bristol Myers Squibb actively exploring partnerships to enhance their product portfolios in the local market.

Future Outlook

South Korea Inflammatory Bowel Disease Treatment Market Future Outlook

The Inflammatory Bowel Disease Treatment Market is projected to grow at a 5.52% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options.

New opportunities lie in:

  • Development of personalized biologic therapies for targeted patient populations.
  • Expansion of telehealth services for remote patient monitoring and consultations.
  • Investment in AI-driven diagnostic tools to enhance treatment accuracy and efficiency.

By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms.

Market Segmentation

South Korea Inflammatory Bowel Disease Treatment Market Type Outlook

  • Aminosalicylates
  • Corticosteroids
  • Immunomodulators
  • Biologics
  • Antibiotics

South Korea Inflammatory Bowel Disease Treatment Market End User Outlook

  • Hospitals
  • Ambulatory Surgical Centers
  • Homecare Settings

South Korea Inflammatory Bowel Disease Treatment Market Disease Type Outlook

  • Ulcerative Colitis
  • Crohn's Disease

South Korea Inflammatory Bowel Disease Treatment Market Route of Administration Outlook

  • Oral
  • Injectable
  • Topical

Report Scope

MARKET SIZE 2024 600.0(USD Million)
MARKET SIZE 2025 633.12(USD Million)
MARKET SIZE 2035 1083.75(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 5.52% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled AbbVie (US), Johnson & Johnson (US), Bristol-Myers Squibb (US), Takeda Pharmaceutical Company (JP), Amgen (US), Gilead Sciences (US), Merck & Co. (US), Sanofi (FR), Ferring Pharmaceuticals (CH)
Segments Covered Type, Route of Administration, Disease Type, End User
Key Market Opportunities Emerging biologics and personalized therapies enhance treatment options in the inflammatory bowel-disease-treatment market.
Key Market Dynamics Rising demand for innovative therapies drives competition in the inflammatory bowel-disease-treatment market in South Korea.
Countries Covered South Korea
Author
Author
Author Profile
Satyendra Maurya LinkedIn
Research Analyst
An accomplished research analyst with high proficiency in market forecasting, data visualization, competitive benchmarking, and others. He holds a pronounced track record in research and consulting projects for sectors such as life sciences, medical devices, and healthcare IT. His capabilities in qualitative and quantitative analysis have resulted in positive client outcomes. Working on niche market trends, opportunities, sales, and forecasted value is part of his skill set.
Co-Author
Co-Author Profile
Garvit Vyas LinkedIn
Vice President - Operations
Garvit Vyas is a Research Analyst with experience in working across multiple industry domains in the market research sector. Over the past four years, he has been actively involved in analyzing diverse markets, gathering industry insights, and contributing to the development of comprehensive research reports. His work includes studying market trends, evaluating competitive landscapes, and supporting data-driven business insights. In the early phase of his career, Garvit worked on cross-domain research projects, which helped him build a strong foundation in market analysis, data interpretation, and industry intelligence across various sectors. Later, he transitioned into the Quality Control (QC) function, where he focuses on reviewing and refining research reports and marketing collaterals to ensure accuracy, consistency, and high editorial standards. His responsibilities include validating research data, improving report structure, and maintaining the overall quality of published content. Garvit is committed to maintaining strong research integrity and delivering reliable insights that support informed business decision-making.
Get In Touch
Leave a Comment

FAQs

What is the current valuation of the South Korea inflammatory bowel-disease-treatment market?

<p>The market valuation was $600.0 Million in 2024.</p>

What is the projected market size for the South Korea inflammatory bowel-disease-treatment market by 2035?

<p>The projected valuation for 2035 is $1,083.75 Million.</p>

What is the expected CAGR for the South Korea inflammatory bowel-disease-treatment market during the forecast period 2025 - 2035?

<p>The expected CAGR is 5.52% during the forecast period.</p>

Which companies are the key players in the South Korea inflammatory bowel-disease-treatment market?

<p>Key players include AbbVie, Johnson & Johnson, Bristol-Myers Squibb, Takeda Pharmaceutical Company, Amgen, Gilead Sciences, Merck & Co., Sanofi, and Ferring Pharmaceuticals.</p>

What are the main segments of the South Korea inflammatory bowel-disease-treatment market?

<p>The main segments include Type, Route of Administration, Disease Type, and End User.</p>

What was the market size for biologics in the South Korea inflammatory bowel-disease-treatment market in 2024?

<p>The market size for biologics was $250.0 Million in 2024.</p>

How much is the market for immunomodulators projected to grow by 2035?

<p>The market for immunomodulators is projected to grow to $180.0 Million by 2035.</p>

What is the market size for Crohn's Disease treatment in 2024?

<p>The market size for Crohn's Disease treatment was $300.0 Million in 2024.</p>

Which route of administration has the highest projected market size in 2035?

<p>The injectable route is projected to have the highest market size at $550.0 Million in 2035.</p>

What is the expected market size for hospitals as an end user by 2035?

<p>The expected market size for hospitals as an end user is projected to reach $540.0 Million by 2035.</p>

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓
%>